Search

Your search keyword '"Mathieu Lesouhaitier"' showing total 2 results
Start Over Author "Mathieu Lesouhaitier" Journal ssrn electronic journal
2 results on '"Mathieu Lesouhaitier"'

1. High Prevalence of Fungal Infections in Mechanically Ventilated COVID-19 Patients in the ICU: The French Multicenter MYCOVID Study

Author

Jean-Christophe Richard, Nicolas de Prost, Yves Cohen, Sylvie Paulus, Dorothée Quinio, Melek Manai, Carole Schwebel, Florence Persat, Antoine Berry, Cécile Garnaud, Lionel Lamhaut, Florian Reizine, Jordan Leroy, Hélène Guegan, Béatrice Riu-Poulenc, Jean Marc Tadie, Muriel Cornet, Antoine Monsel, Arnaud Fekkar, Guillaume Desoubeaux, Ferhat Meziani, Marie Soulié, Jean-Pierre Gangneux, Florence Robert-Gangneux, Nicolas Terzi, Mathieu Lesouhaitier, Yves Le Tulzo, Christine Bonnal, Bruno Mégarbane, Valérie Letscher-Bru, Guillaume Voiriot, Gilles Nevez, Brice Autier, Jean-François Timsit, Nadine François, Jean Menotti, Frederique Boquel, Patrice Le Pape, Christophe Hennequin, Xavier Iriart, Estelle Cateau, Charles Edouard Luyt, Francoise Botterel, Florent Wallet, Solène Le Gal, Philippe Seguin, Julien Mayaux, Jean-Ralph Zahar, Marie-Elisabeth Bougnoux, Bruno Laviolle, Estelle Sabourin, Sophie Brun, Jeff Morcet, Laurent Argaud, Juliette Guitard, Emmanuel Canet, Alexandre Alanio, Cécile Aubron, Saad Nseir, Florent Morio, Romain Pelletier, Marion Blaize, Damien Dupont, Ana Novara, Boualem Sendid, Stephan Ehrmann, Sandrine Houze, Eric Dannaoui, Sorya Belaz, and Arnaud W. Thille

Subjects
Mechanical ventilation, medicine.medical_specialty, High prevalence, Coronavirus disease 2019 (COVID-19), business.industry, medicine.medical_treatment, Emergency medicine, medicine, business, Dexamethasone, medicine.drug
Published
2021

2. Mass Cytometry and Artificial Intelligence Define CD169 as a Marker of SARS-CoV2-Induced Acute Respiratory Distress Syndrome

Author

Isabelle Bezier, Jean Feuillard, Murielle Gregoire, Juliette Ferrant, Mikael Roussel, Michel Cogné, Maelle Latour, Joelle Dulong, Mathieu Lesouhaitier, Angelique Vinit, Marie Cornic, Simon Léonard, Jean Marc Tadié, Sarah H. Carl, Simon Le Gallou, Florian Reizine, Nadège Bescher, Clothilde Verdy, Vijay K. Tiwari, and Karin Tarte

Subjects
ARDS, business.industry, medicine.disease, Intensive care unit, law.invention, Cog, Informed consent, law, Medicine, Artificial intelligence, Fast track, business, Complication, Adverse effect, Declaration of Helsinki
Abstract

Acute respiratory distress syndrome (ARDS) is the main complication of COVID-19, requiring admission to Intensive Care Unit (ICU). Despite extensive immune profiling of COVID-19 patients, to what extent COVID-19-associated ARDS specifically differs from other causes of ARDS remains unknown. To address this crucial question, we built 3 cohorts of patients categorized in COVID-19neg ARDSpos, COVID-19pos ARDSpos, and COVID-19pos ARDSneg, and compared their immune landscape analyzed by high-dimensional mass cytometry on peripheral blood followed by artificial intelligence analysis. A cell signature associating S100A9/calprotectin-producing CD169pos monocytes, plasmablasts, and Th1 cells was specifically found in COVID-19pos ARDSpos, unlike COVID-19neg ARDSpos patients. Moreover, this signature was essentially shared with COVID-19pos ARDSneg patients, suggesting that severe COVID-19 patients, whatever they experienced or not ARDS, display similar immune profiles. We also showed an increase in CD14pos HLA-DRlow and CD14low CD16pos monocytes correlated to the occurrence of adverse events during ICU stay. Our study demonstrates that COVID-19-associated ARDS display a specific immune profile, and might benefit from personalized therapy in addition to standard ARDS management. Funding: This work was supported by the University hospital of Rennes, CFTR² (COVID-19 Fast Track Recherche Rennes) grant (to F.R.)and by the Fondation pour la Recherche Medicale (FRM) and the Agence Nationale de la Recherche (ANR), Flash Covid-19 joint grant (HARMONICOV to M.Cog.) Conflict of Interest: J.Fer., F.R., S.L.G., J.D., M.Le., M.G., N.B., C.V., M.La., I.B., M.Cor., S.L., J.Feu., M. Cog. declare no competing interest. M.R., S.C., V.K.T., J.M.T., and K.T. are the inventors of a patent EP 20305642.9 “A method for early detection of propensity to severe clinical manifestations Methods” submitted June 11th 2020 under University hospital of Rennes and Scailyte AG names. Ethical Approval: The study design was approved by our ethic committee (CHU Rennes, n°35RC20_9795_HARMONICOV, ClinicalTrials.gov Identifier: NCT04373200) and informed consent was obtained from patients in accordance with the Declaration of Helsinki.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results